Search Result

Results for "

IL-17 inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Interleukin Related (62) Adenosine Deaminase (1) Akt (1) Androgen Receptor (1) Apoptosis (4) Aryl Hydrocarbon Receptor (1) Bacterial (2) Bcr-Abl (1) Caspase (1) CD3 (1) CXCR (1) Cytochrome P450 (1) DNA/RNA Synthesis (2) Endogenous Metabolite (1) Epigenetic Reader Domain (1) FAAH (1) Ferroptosis (1) FGFR (1) Fungal (1) G Protein-coupled Receptor Kinase (GRK) (1) Glutathione Peroxidase (2) Glutathione S-transferase (2) GSK-3 (1) Histone Acetyltransferase (1) IFNAR (6) Isotope-Labeled Compounds (1) JAK (3) Keap1-Nrf2 (1) Lipoxygenase (1) Mitophagy (1) MMP (2) Necroptosis (2) NF-κB (6) NO Synthase (1) Notch (2) p38 MAPK (1) PARP (2) Phosphodiesterase (PDE) (1) PI3K (1) PINK1/Parkin (1) PKC (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) RIP kinase (1) ROR (12) SOD (2) STAT (5) TGF-beta/Smad (1) TNF Receptor (7) Toll-like Receptor (TLR) (3) Tyrosine Hydroxylase (1) VEGFR (1) β-catenin (1)
By Research Areas:	Cancer (15) Infection (5) Inflammation/Immunology (75) Metabolic Disease (6) Neurological Disease (4)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Targets Recommended: Interleukin Related IRAK Serpin Itk

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15826

SGC-CBP30 Maximum Cited Publications 20 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
SGC-CBP30, a chemical probe, is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .

HY-P99248

Risankizumab Risankizumab rzaa; BI 655066; ABBV-066	Interleukin Related	Inflammation/Immunology
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (K_d <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC₅₀ = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .

HY-139206

LY3509754 4 Publications Verification IL-17A inhibitor 1	Interleukin Related	Inflammation/Immunology
LY3509754 (IL-17A inhibitor 1) is a *IL-17A* inhibitor, with IC₅₀ values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells .

HY-P990222

Anti-Mouse/Rat IL-17A Antibody (17F3) 1 Publications Verification	Interleukin Related	Infection Metabolic Disease Inflammation/Immunology
Anti-Mouse/Rat IL-17A Antibody (17F3) is a mouse-derived IgG1κ type antibody inhibitor, targeting to mouse and rat *IL-17A. Anti-Mouse IL-17A* Antibody (17F3) can neutralize IL-17. Anti-Mouse/Rat IL-17A Antibody (17F3) can be used for the researches of infection, immunology and metabolic disease, such as M.intracellulare infection and diabetes .

HY-15898

Y-320 5 Publications Verification	Interleukin Related Apoptosis	Inflammation/Immunology Cancer
Y-320 is a potent, orally active phenylpyrazoleanilide immunomodulator. Y-320 inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC₅₀ values of 20 to 60 nM. Y-320 enhances TP53, DMD, and COL17A1 PTC readthrough by G418 and increases cellular protein levels and protein synthesis. Y-320 concomitants use of with a low dose of Paclitaxel (HY-B0015) significantly sensitized multidrug resistance (MDR) tumors by inducing G2/M phase arrest and apoptosis. Y-320 can be used for research of rheumatoid arthritis (RA) and cancer .

HY-153780

Navepdekinra DC-806; LY4100504; S-011806	Interleukin Related	Inflammation/Immunology
Navepdekinra (DC-806) is an orally active, potent interleukin-17A (IL-17A) inhibitor (IC₅₀ = 10.81 nM). Navepdekinra disrupts the IL-17A protein-receptor interaction, suppressing the downstream pro-inflammatory signaling pathway. Navepdekinra inhibits arthritis in a collage-induced arthritis (CIA) rat model. Navepdekinra can be used for psoriasis, psoriatic arthritis, and ankylosing spondylitis .

HY-N3029

Noreugenin 2 Publications Verification	Interleukin Related Apoptosis Glutathione Peroxidase SOD Glutathione S-transferase Necroptosis	Inflammation/Immunology
Noreugenin is a phenolic compound found in Calea uniflora Less. Noreugenin inhibits myeloperoxidase activity and reduces levels of proinflammatory cytokines IL-1β and *IL-17A* levels in LPS (HY-D1056)-induced murine pleurisy model. Noreugenin reduces apoptosis and necrosis. Noreugenin reduces lipid peroxidation, and antioxidant enzyme (CAT, SOD, GST) activity. Noreugenin exhibits anti-inflammatory and antioxidant effects. Noreugenin can be used for the research of inflammatory conditions, such as pleurisy .

HY-153701S

Envudeucitinibum Envudeucitinib; ESK-001	JAK Interleukin Related IFNAR Isotope-Labeled Compounds	Inflammation/Immunology
Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, *IL-17, and type I interferons (IFNs)*. Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

HY-P991598

MOR-106 MOR12743; MOR03207	Interleukin Related NF-κB	Inflammation/Immunology
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC₅₀ = 59 pM for human IL-17C, IC₅₀ = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .

HY-139780

JNJ-61803534	ROR	Inflammation/Immunology
JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC₅₀ of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions .

HY-107390A

AX-024 hydrochloride 3 Publications Verification	TNF Receptor Interleukin Related IFNAR	Inflammation/Immunology Cancer
AX-024 hydrochloride is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC₅₀ ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting SH3 domains. AX-024 hydrochloride has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and *IL-17A*.

HY-107390

AX-024 3 Publications Verification	TNF Receptor Interleukin Related IFNAR	Inflammation/Immunology Cancer
AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC₅₀ ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and *IL-17A*.

HY-P991266

SM-17	Interleukin Related	Inflammation/Immunology
SM-17 is a humanized monoclonal antibody inhibitor targeting interleukin 25 (IL-25) and interleukin-17 receptor B (IL17RB). SM-17 is promising for research of immune system diseases .

HY-19770

GSK2981278 4 Publications Verification	ROR	Inflammation/Immunology
GSK2981278 is a potent and selective RORγ inverse agonist. GSK2981278 inhibits activation of the il17 promoter and interferes RORγ-DNA binding .

HY-P99124

Anti-Mouse CD3 Antibody (17A2) 1 Publications Verification	CD3	Inflammation/Immunology
Anti-Mouse CD3 Antibody (17A2) is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat. Anti-Mouse CD3 Antibody (17A2) enhances T-cell proliferation and activation and stimulate IFN-γ or IL-17 production in splenic T cells. Anti-Mouse CD3 Antibody (17A2) significantly suppresses mortality in Graft-versus-host disease (GVHD) mice models .

HY-126328

PKC-theta inhibitor 1	PKC Interleukin Related	Inflammation/Immunology
PKC-theta inhibitor 1 is an orally active and selective ATP-competitive inhibitor of Protein Kinase Cθ (PKCθ), with a K_i value of 6 nM. PKC-theta inhibitor 1 inhibits T-cell-mediated inflammatory responses by suppressing the release of proinflammatory cytokines (IL-2 IC₅₀ = 0.21 μM in anti-CD3/CD28-stimulated PBMCs; *IL-17* IC₅₀ = 1 μM in CD3/CD28-stimulated Th17 cells) PKC-theta inhibitor 1 significantly reduces symptoms in mice with ongoing experimental autoimmune encephalomyelitis (EAE). PKC-theta inhibitor 1 can be used for the study of T-cell-mediated inflammatory diseases such as multiple sclerosis .

HY-P99335

Vunakizumab Anti-Human IL17A Recombinant Antibody; SHR-1314	Interleukin Related	Inflammation/Immunology
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis .

HY-P99515

Xeligekimab GR 1501	Interleukin Related	Inflammation/Immunology
Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonal antibody. Xeligekimab inhibits the pro-inflammatory cascade. Xeligekimab can be used for the research of inflammatory disease, such as radiographic axial spondyloarthritis .

HY-124686

ER-464195-01	STAT Interleukin Related TNF Receptor	Inflammation/Immunology
ER-464195-01 is an orally active calreticulin (CRT) and integrin α subunits (ITGAs) binding inhibitor. ER-464195-01 inhibits leukocyte infiltration and subsequent inflammatory cascade reactions by dissociating the binding between CRT and ITGA. ER-464195-01 down-regulates the expression of pro-inflammatory genes (such as TNF-α, IL-1β, IL-6, *IL-17f) induced by DSS (HY-116282C), and inhibit* the phosphorylation of STAT3 and the production of serum amyloid A (SAA). ER-464195-01 can be used for the study of inflammatory bowel disease (IBD) .

HY-N0902

Dihydrosanguinarine 13,14-Dihydrosanguinarine	Fungal Bacterial Interleukin Related	Infection Inflammation/Immunology
Dihydrosanguinarine (13,14-Dihydrosanguinarine) is an alkaloid with antibacterial and anti-inflammatory activities, and also an important precursor of Sanguinarine (HY-N0052). Dihydrosanguinarine targets and regulates the *TNF/IL-17/PI3K* signaling pathway, downregulates the levels of pro-inflammatory factors such as *IL-17A, TNF-α* and IL-6, upregulates the expression of TGF-β, inhibits myeloperoxidase activity, and regulates the transcription of multiple inflammation-related genes. Dihydrosanguinarine exhibits antibacterial activity against a variety of oral microorganisms. Dihydrosanguinarine can be used in research related to liver inflammation and oral flora dysbiosis .

HY-145429

IL-17A modulator-2 2 Publications Verification	Interleukin Related	Neurological Disease Inflammation/Immunology Cancer
IL-17A modulator-2 is a *IL-17A* modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC₅₀ of 8.3. IL-17A modulator-2 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .

HY-P5963

Lib2-1	Interleukin Related	Inflammation/Immunology
Lib2-1, a macrocyclic peptide, is an IL-17C/IL-17RE interaction inhibitor. Lib2-1 can be used for autoimmune and inflammatory diseases research .

HY-155830

Morcamilast ME3183; PDE4-IN-14	Phosphodiesterase (PDE) Interleukin Related	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Morcamilast (ME3183) is a selective and orally active PDE4 inhibitor, with IC₅₀s of 1.28 nM (PDE4A1A), 2.33 nM (PDE4B1), and 1.63 nM (PDE4D2) respectively. Morcamilast shows weak inhibition of PDEs other than PDE4s Morcamilast is an anti-inflammatory agent and inhibits LPS (HY-D1056)-induced release of TNF-α, IL-12/23p40, IL-23, and *IL-17A* in human PBMCs and T cells. Morcamilast has antipruritic effect and can be used in the study of psoriasis, atopic dermatitis, and other inflammatory diseases .

HY-164826

Acetyl zingerone	Interleukin Related Reactive Oxygen Species (ROS) MMP Pyroptosis Ferroptosis Notch Keap1-Nrf2 PINK1/Parkin Mitophagy Caspase Apoptosis	Inflammation/Immunology Cancer
Acetyl zingerone is an analog of Zingerone (HY-14621). Acetyl zingerone downregulates the expression of ROS metabolism-related genes, fibroblast senescence-related genes, keratinocyte differentiation-related genes, and *IL-17A* target genes. Acetyl zingerone inhibits the activities of MMP-1, MMP-3, and MMP-12, as well as the activation of NLRP3 inflammasome, pyroptosis (pyroptosis), ferroptosis (ferroptosis), cartilage destruction, and UVA-induced cyclobutane pyrimidine dimer formation. Acetyl zingerone upregulates the expression of collagen, proteoglycan, extracellular matrix glycoprotein, Notch pathway, and GPX4 gene, activates Nrf2 and HO-1, induces extracellular matrix synthesis and PINK1/Parkin-mediated mitophagy (mitophagy), and promotes chondrocyte survival. Acetyl zingerone alleviates the progression of osteoarthritis in mice . Acetyl zingerone can be used in research related to skin aging, inflammatory skin diseases, osteoarthritis, melanoma, and non-melanoma skin cancer .

HY-P990221

Anti-Mouse IL-17F Antibody (MM17F8F5.1A9)	Interleukin Related	Infection Neurological Disease Cancer
Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse *IL-17F. Anti-Mouse IL-17F* Antibody (MM17F8F5.1A9) can neutralize IL-17. Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) can be used for the researches of cancer, infection and neurological disease, such as Alzheimer’s disease (AD) and pancreatic cancer .

HY-120785

SR1555	ROR	Inflammation/Immunology
SR1555 is a specific retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inverse agonist with an IC₅₀ value of 1 μM. SR1555 not only inhibits TH17 cell development and function but also increases the frequency of T regulatory cells, as well as inhibits the expression of IL-17. SR1555 can be used for researching autoimmune diseases .

HY-148272

IL-17A modulator-3	Interleukin Related	Inflammation/Immunology Cancer
IL-17A modulator-3 (compound 253) is a *IL-17A* modulator. IL-17A modulator-3 inhibits IL-17A/A with an IC₅₀ value ＜10 μM. IL-17A modulator-3 can be used for the research of inflammation, cancer and autoimmune disease .

HY-145430

IL-17A modulator-1	Interleukin Related	Neurological Disease Inflammation/Immunology Cancer
IL-17A modulator-1 is a *IL-17A* modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC₅₀ of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .

HY-103637

Vimirogant VTP-43742	ROR	Inflammation/Immunology
Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor (K_i=3.5 nM; IC₅₀=17 nM). Vimirogant exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC₅₀=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant has the potential for autoimmune disorders research .

HY-136527

BMS-986251	ROR Interleukin Related	Inflammation/Immunology
BMS-986251 is an orally active and selective RORγt inverse agonist with an EC₅₀ of 12 nM for RORγt GAL4. BMS-986251 inhibits *IL-17* with an EC₅₀ of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced (HY-B0180) models (preclinical models of psoriasis) .

HY-139686

IL-17A inhibitor 2	Interleukin Related	Inflammation/Immunology
IL-17A inhibitor 2 is an *IL-17A* inhibitor for researching psoriasis, rheumatoid arthritis, and multiple sclerosis.

HY-103637A

Vimirogant hydrochloride 1 Publications Verification VTP-43742 hydrochloride	ROR	Inflammation/Immunology
Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor (K_i=3.5 nM; IC₅₀=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC₅₀=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant hydrochloride has the potential for autoimmune disorders research .

HY-155244

12R-LOX-IN-2	Lipoxygenase DNA/RNA Synthesis	Inflammation/Immunology
12R-LOX-IN-2 (compound 7b) is an inhibitor of 12R-lipoxygenase (12R-LOX). 12R-LOX-IN-2 inhibits imiquimod (IMQ)-induced hyperproliferation of psoriatic keratinocytes and suppresses colony formation. 12R-LOX-IN-2 also reduced the protein level of Ki67 and the mRNA expression of IL-17A in IMQ-induced cells. 12R-LOX-IN-2 can be used in research into psoriasis and other skin-related inflammatory diseases .

HY-147128

PY109	Aryl Hydrocarbon Receptor Cytochrome P450 Interleukin Related	Inflammation/Immunology
PY109 is an orally active and highly selective aryl hydrocarbon receptor (AHR) agonist. PY109's EC₅₀ values in human-derived HepG2 and mouse Hepa-1c1c7 cells are 1.2 nM and 1.4 nM respectively. PY109 significantly upregulates the expression of CYP1A1 and IL-22, and inhibits the expression of IL-17A. PY109 significantly improves colitis in mice. PY109 can be used for research on colitis .

HY-178714

JNJ627	Interleukin Related	Inflammation/Immunology
JNJ627 is a small molecule allosteric inhibitor of *IL-17A* with a K_D of 92 nM. JNJ627 effectively inhibits the binding of IL-17A and IL-17RA, with an IC₅₀ value of 16 nM. JNJ627 is capable of inhibiting the secretion of G-CSF (granulocyte colony-stimulating factor) caused by IL-17A stimulation. JNJ627 can be used for the study of autoimmune diseases (such as psoriasis) .

HY-P991596

ANB004	Interleukin Related	Inflammation/Immunology
ANB004 is a humanized monoclonal antibody inhibitor, targeting *IL-17*. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .

HY-160040

Cobitolimod	Toll-like Receptor (TLR)	Inflammation/Immunology
Cobitolimod is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod suppresses Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-P991274

BMS-986010	Interleukin Related	Inflammation/Immunology
BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease .

HY-127023

Eicosapentaenoyl serotonin EPA-5-HT	Endogenous Metabolite FAAH Interleukin Related Tyrosine Hydroxylase	Metabolic Disease
Eicosapentaenoyl serotonin (EPA-5-HT) is an endogenous fatty acid-serotonin conjugate lipid mediator. Eicosapentaenoyl serotonin acts as an inhibitor of fatty acid amide hydrolase (FAAH). Eicosapentaenoyl serotonin suppresses *IL-17* release in Concanavalin A (HY-P2149)-stimulated human peripheral blood mononuclear cells. Eicosapentaenoyl serotonin is regulated by polyunsaturated fatty acids and modulates intestinal immunity and Th17 signaling. Eicosapentaenoyl serotonin can be used for the study of inflammatory bowel disease-related mechanisms .

HY-P991091

COVA322	TNF Receptor Interleukin Related	Inflammation/Immunology
COVA322 is a bispecific TNF and *IL-17A* antibody. COVA322 inhibits simultaneously TNF and the IL-17A homodimer that can be used for the study of inflammatory diseases .

HY-158159

IL17A-IN-1	Interleukin Related	Inflammation/Immunology Cancer
IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .

HY-168971

Paeoniflorin-6′-O-benzene sulfonate CP-25	IFNAR STAT TNF Receptor Interleukin Related CXCR JAK G Protein-coupled Receptor Kinase (GRK)	Inflammation/Immunology
Paeoniflorin-6′-O-benzene sulfonate (CP-25) is the inhibitor for G protein-coupled receptor kinase 2 (GRK2) that inhibits the translocation of GRK2 to the cell membrane, inhibits JAK1/STAT3 signaling pathway. Paeoniflorin-6′-O-benzene sulfonate inhibits IL-17A/CXCL2-induced proliferation of HaCaT. Paeoniflorin-6′-O-benzene sulfonate reduces the levels of inflammatory factors and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3 and CXCL9, alleviates Imiquimod (HY-B0180)-induced psoriasis in mouse model .

HY-162490

TF-S14	ROR	Inflammation/Immunology
TF-S14 is a reverse agonist of RORγt. TF-S14 reduces Th17 cell-associated cytokine production, including IL-17A, IL-21, and IL-22 by binding to and inhibiting RORγt activity. TF-S14 can be used in the study of autoimmune diseases and rejection in allotransplantation .

HY-172806

PARP14 inhibitor 1	PARP Interleukin Related	Inflammation/Immunology
PARP14 inhibitor 1 is an orally active, selective PARP14 inhibitor with an IC₅₀ of 5.52 nM. PARP14 inhibitor 1 exhibits favorable pharmacokinetic properties and in vivo safety. PARP14 inhibitor 1 enhances and stabilizes intracellular endogenous PARP14 protein levels, while effectively reducing the expression levels of IL-4, IL-13 and *IL-17A. PARP14 inhibitor* 1 can be used in research related to atopic dermatitis .

HY-145434

IL-17 modulator 5	Interleukin Related	Inflammation/Immunology
IL-17 modulator 5 (compound 26) is a *IL-17* inhibitor, with an IC₅₀ of 1 nM .

HY-144373

IL-17 modulator 6	Interleukin Related	Inflammation/Immunology
IL-17 modulator 6 (compound 61) is a potent *Interleukin 17 (IL-17)* modulator (pIC₅₀=9.1). IL-17 modulator 6 has the ability to inhibit IL-17 and can be used for the research of inflammatory and autoimmune diseases .**

HY-168582

IL-17-IN-2	Interleukin Related	Inflammation/Immunology
IL-17-IN-2 (Example 51) is a potent inhibitor of *IL-17, with the IC₅₀* of < 0.4 μM in HTRF and NHK assay .

HY-168084

IL-17-IN-1	Interleukin Related	Inflammation/Immunology
IL-17-IN-1 (26) is an orally active *IL-17* inhibitor, with IC₅₀ values of 0.013 μM and 0.004 μM for IL-17A and IL-6 release, respectively. IL-17-IN-1 (26) effectively reduces knee swelling in a rat arthritis model .

HY-160040A

Cobitolimod sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Cobitolimod sodium is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod sodium inhibits Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-131397

Docosahexaenoyl serotonin DHA-5-HT	Interleukin Related	Inflammation/Immunology
Docosahexaenoyl serotonin (DHA-5-HT) is an endogenous n-3 fatty acid-serotonin conjugate. Docosahexaenoyl serotonin is an inhibitor of *IL-17*. Docosahexaenoyl serotonin has anti-inflammatory activity .

Cat. No.	Product Name	Type

HY-12292G

IM-12

Fluorescent Dyes

IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS and COX-2, and induces ER stress, Ca ²⁺ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABL ^T315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia .

Cat. No.	Product Name	Type

HY-12292G

IM-12

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P5963

Lib2-1	Interleukin Related	Inflammation/Immunology
Lib2-1, a macrocyclic peptide, is an IL-17C/IL-17RE interaction inhibitor. Lib2-1 can be used for autoimmune and inflammatory diseases research .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99248

Risankizumab Risankizumab rzaa; BI 655066; ABBV-066	Interleukin Related	Inflammation/Immunology
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (K_d <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC₅₀ = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .

HY-P990222

Anti-Mouse/Rat IL-17A Antibody (17F3) 1 Publications Verification	Interleukin Related	Infection Metabolic Disease Inflammation/Immunology
Anti-Mouse/Rat IL-17A Antibody (17F3) is a mouse-derived IgG1κ type antibody inhibitor, targeting to mouse and rat *IL-17A. Anti-Mouse IL-17A* Antibody (17F3) can neutralize IL-17. Anti-Mouse/Rat IL-17A Antibody (17F3) can be used for the researches of infection, immunology and metabolic disease, such as M.intracellulare infection and diabetes .

HY-P991598

MOR-106 MOR12743; MOR03207	Interleukin Related NF-κB	Inflammation/Immunology
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC₅₀ = 59 pM for human IL-17C, IC₅₀ = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .

HY-P991266

SM-17	Interleukin Related	Inflammation/Immunology
SM-17 is a humanized monoclonal antibody inhibitor targeting interleukin 25 (IL-25) and interleukin-17 receptor B (IL17RB). SM-17 is promising for research of immune system diseases .

HY-P99124

Anti-Mouse CD3 Antibody (17A2) 1 Publications Verification	CD3	Inflammation/Immunology
Anti-Mouse CD3 Antibody (17A2) is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat. Anti-Mouse CD3 Antibody (17A2) enhances T-cell proliferation and activation and stimulate IFN-γ or IL-17 production in splenic T cells. Anti-Mouse CD3 Antibody (17A2) significantly suppresses mortality in Graft-versus-host disease (GVHD) mice models .

HY-P99335

Vunakizumab Anti-Human IL17A Recombinant Antibody; SHR-1314	Interleukin Related	Inflammation/Immunology
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis .

HY-P99515

Xeligekimab GR 1501	Interleukin Related	Inflammation/Immunology
Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonal antibody. Xeligekimab inhibits the pro-inflammatory cascade. Xeligekimab can be used for the research of inflammatory disease, such as radiographic axial spondyloarthritis .

HY-P990221

Anti-Mouse IL-17F Antibody (MM17F8F5.1A9)	Interleukin Related	Infection Neurological Disease Cancer
Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse *IL-17F. Anti-Mouse IL-17F* Antibody (MM17F8F5.1A9) can neutralize IL-17. Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) can be used for the researches of cancer, infection and neurological disease, such as Alzheimer’s disease (AD) and pancreatic cancer .

HY-P991596

ANB004	Interleukin Related	Inflammation/Immunology
ANB004 is a humanized monoclonal antibody inhibitor, targeting *IL-17*. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .

HY-P991274

BMS-986010	Interleukin Related	Inflammation/Immunology
BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease .

HY-P991091

COVA322	TNF Receptor Interleukin Related	Inflammation/Immunology
COVA322 is a bispecific TNF and *IL-17A* antibody. COVA322 inhibits simultaneously TNF and the IL-17A homodimer that can be used for the study of inflammatory diseases .

HY-P991261

CJM-112	Interleukin Related	Inflammation/Immunology
CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways .

HY-P991595

HB-0017	Interleukin Related	Inflammation/Immunology
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting *IL-17A. HB-0017 inhibits* the IL-6 secretion induced by IL-17A with an IC₅₀ of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991260

CNTO-6785	Interleukin Related	Infection
CNTO-6785 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .

HY-P991263

SCH-900117	Interleukin Related	Inflammation/Immunology
SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .

HY-P990252

Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2)	Notch Interleukin Related NF-κB VEGFR FGFR NO Synthase	Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and *IL-17A* production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3029

Noreugenin 2 Publications Verification	Structural Classification Natural Products Rhododendron dauricum Linn. Classification of Application Fields Plants Aloe arborescens Liliaceae Other Diseases Phenols Polyphenols Ericaceae Disease Research Fields Source Classification	Interleukin Related Apoptosis Glutathione Peroxidase SOD Glutathione S-transferase Necroptosis
Noreugenin is a phenolic compound found in Calea uniflora Less. Noreugenin inhibits myeloperoxidase activity and reduces levels of proinflammatory cytokines IL-1β and *IL-17A* levels in LPS (HY-D1056)-induced murine pleurisy model. Noreugenin reduces apoptosis and necrosis. Noreugenin reduces lipid peroxidation, and antioxidant enzyme (CAT, SOD, GST) activity. Noreugenin exhibits anti-inflammatory and antioxidant effects. Noreugenin can be used for the research of inflammatory conditions, such as pleurisy .

HY-N0902

Dihydrosanguinarine 13,14-Dihydrosanguinarine	Infection Alkaloids Structural Classification Classification of Application Fields Quinoline Alkaloids Macleaya cordata (Willd.) R. Br. Plants Disease Research Fields Papaveraceae Source Classification	Fungal Bacterial Interleukin Related
Dihydrosanguinarine (13,14-Dihydrosanguinarine) is an alkaloid with antibacterial and anti-inflammatory activities, and also an important precursor of Sanguinarine (HY-N0052). Dihydrosanguinarine targets and regulates the *TNF/IL-17/PI3K* signaling pathway, downregulates the levels of pro-inflammatory factors such as *IL-17A, TNF-α* and IL-6, upregulates the expression of TGF-β, inhibits myeloperoxidase activity, and regulates the transcription of multiple inflammation-related genes. Dihydrosanguinarine exhibits antibacterial activity against a variety of oral microorganisms. Dihydrosanguinarine can be used in research related to liver inflammation and oral flora dysbiosis .

HY-N11768

4-Methoxylonchocarpin	Monophenols Phenols Plants Moraceae Dorstenia mannii Hook.f. Source Classification	NF-κB Interleukin Related Toll-like Receptor (TLR)
4-Methoxylonchocarpin is an orally active anti-inflammatory agent. 4-methoxylonchocarpin inhibits the binding of LPS to Toll-like Receptor (TLR) TLR4 to inhibit NF-κB activation and TNF Receptor and IL-6 expression. 4-Methoxylonchocarpin also inhibits the phosphorylation of TGF-beta activated kinase 1 and TNBS-induced expression of IL-1β, IL-17A, and TNF. 4-methoxylonchocarpin can improve 2,4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis mouse model .

HY-N3029R

Noreugenin (Standard)	Aloe arborescens Structural Classification Natural Products Liliaceae Rhododendron dauricum Linn. Phenols Polyphenols Ericaceae Plants Source Classification	Reference Standards Interleukin Related Apoptosis Glutathione Peroxidase SOD Glutathione S-transferase
Noreugenin (Standard) is the analytical standard of Noreugenin. This product is intended for research and analytical applications. Noreugenin is a phenolic compound found in Calea uniflora Less. Noreugenin inhibits myeloperoxidase activity and reduces levels of proinflammatory cytokines IL-1β and *IL-17A* levels in LPS (HY-D1056)-induced murine pleurisy model. Noreugenin reduces apoptosis and necrosis. Noreugenin reduces lipid peroxidation, and antioxidant enzyme (CAT, SOD, GST) activity. Noreugenin exhibits anti-inflammatory and antioxidant effects. Noreugenin can be used for the research of inflammatory conditions, such as pleurisy .

HY-N12481

Cephalandole B	Alkaloids Acanthaceae Plants Indole Alkaloids Jacobaea cannabifolia (Less.) E. Wiebe Source Classification	Others
Cephalandole B is an indigo alkaloid that has the activity of inhibiting IL-17A gene expression. Cephalandole B significantly inhibited the activity of IL-17A luciferase reporter gene in Jukat cells, and this inhibitory effect was dose-dependent. Cephalandole B may have important application prospects in inflammation-related research .

HY-N8529

Eupalestin	Structural Classification Flavonoids Flavones Lupinus perennis L. Plants Compositae Source Classification	NF-κB p38 MAPK Adenosine Deaminase Interleukin Related
Eupalestin is an anti-inflammatory agent. Eupalestin reduces the levels of p-p65 NF-κB and p-p38 MAPK. Eupalestin inhibits MPO and adenosine deaminase. Eupalestin decreases the levels of pro-inflammatory cytokines including *IL-17A, IL-6, TNF* and IFN-γ. Eupalestin exerts anti-inflammatory activity in a carrageenan (HY-125474)-induced mouse pleurisy model .

Cat. No.	Product Name	Chemical Structure

HY-153701S

Envudeucitinibum

Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

Cat. No.	Product Name		Classification

HY-160040

Cobitolimod		Antisense Oligonucleotides
Cobitolimod is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod suppresses Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-160040A

Cobitolimod sodium		Antisense Oligonucleotides
Cobitolimod sodium is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod sodium inhibits Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

Targets Recommended: Interleukin Related IRAK Serpin Itk

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12292G

IM-12	NF-κB STAT GSK-3 β-catenin Bcr-Abl	Cancer
IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, *IL-17, NO, prostaglandin E2, iNOS* and COX-2, and induces ER stress, Ca ²⁺ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABL ^T315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

IL-17 inhibitors

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Natural
Products